Imugene Ltd
ASX:IMU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Imugene Ltd
Net Issuance of Common Stock
Imugene Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imugene Ltd
ASX:IMU
|
Net Issuance of Common Stock
AU$24.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Issuance of Common Stock
$174.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
CSL Ltd
ASX:CSL
|
Net Issuance of Common Stock
-$370m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
8%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Net Issuance of Common Stock
AU$9.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Issuance of Common Stock
AU$1.8m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Issuance of Common Stock
AU$145.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
29%
|
CAGR 10-Years
31%
|
|
Imugene Ltd
Glance View
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
See Also
What is Imugene Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
24.9m
AUD
Based on the financial report for Dec 31, 2025, Imugene Ltd's Net Issuance of Common Stock amounts to 24.9m AUD.
What is Imugene Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
24%
Over the last year, the Net Issuance of Common Stock growth was -54%. The average annual Net Issuance of Common Stock growth rates for Imugene Ltd have been -35% over the past three years , 25% over the past five years , and 24% over the past ten years .
